The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

According to studies approximately 15% of cancers are caused by viruses. Read more to know about the viruses that cause ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and EMA marketing authorizations ...

My practice included obstetrics, pediatrics and adult care ... Pac-Men tracking down and destroying leukemia cells). Research to develop CAR T-cell therapy began in the 1950s with the development ...

Using human T cells and leukemia cells in specialized mouse models ... of Colorado Hospital and Children's Hospital Colorado – which see more than two million adult and pediatric patient visits yearly ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.